Search

Cancer treatment is complex. For every type of cancer, there is a range of treatments, side effects, and outcomes. Machine learning can help make sense of these variables, according to Quaid Morris.

… Saturday, January 1, 2022 By Julie Grisham Cancer treatment is complex. For every type of cancer, there is a range of treatments, side effects, and outcomes — both short-term and those that arise years later. Machine learning can help make sense of these variables, according to Sloan Kettering Institute

As an autoimmune disease, Type 1 diabetes raises important questions about immune cell activity that have broad implications for immunotherapy.

… Tuesday, November 30, 2021 To an immunologist, autoimmune diseases like Type 1 diabetes are the polar opposite of cancer. In the former, the immune system goes into overdrive and attacks the body’s own organs in a relentless manner, eventually causing disease; with cancer, the immune system shuts down

A recent study led by investigators at MSK and published in Nature Medicine, included a comprehensive analysis of non relapse mortality after CAR T cell therapy in patients with lymphoma and multiple myeloma across multiple clinical trials and real-world studies. In this Q&A we discuss the study's key findings and a new tool for assessing infection risk prior to CAR T cell therapy.

… Monday, July 8, 2024 A Q&A with MSK Visiting Investigator and Research Fellow Dr. Kai Rejeski CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine release

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, June 22, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Selwyn M. Vickers, MD, FACS, President and CEO Selwyn Vickers Named Among 50 Most Influential Clinical Executives by Modern Healthcare Selwyn M. Vickers, MD, FACS , President and

Seventeen scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 17, 2023, as part of Memorial Sloan Kettering’s 44th annual academic convocation.

… Monday, May 15, 2023 This year 17 scientists who did their training at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) are poised to receive their doctorates, the highest number ever to graduate from GSK in a single year. Their years of dedication and training will be recognized

… Wednesday, February 11, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Maximilian Merz Awarded $2.3 Million From the Hector Foundation  Maximilian Merz Maximilian Merz, MD, mmyeloma specialist, has been  awarded $2.3 million by the Hector Foundation

Dendritic cells, the guards of the immune system, have a previously unrecognized division of labor.

… Thursday, October 24, 2019 Summary Scientists at the Sloan Kettering Institute have made a fundamental discovery about how dendritic cells in the immune system are organized into distinct types. The results could inform immunotherapy for cancer and other diseases. Biologists sometimes liken the immune

Memorial Sloan Kettering researchers will lead and present notable research at the American Association for Cancer Research (AACR) Virtual Annual Meeting II.

… Friday, June 19, 2020 Thousands of oncology experts from around the world will tune in virtually June 22-24 for the American Association for Cancer Research (AACR) Virtual Annual Meeting II . Memorial Sloan Kettering (MSK) researchers will lead and present some of the most notable research at the meeting

Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in such programs, driving the need for more accurate decision-making tools such as the 4Kscore test developed at Memorial Sloan Kettering.

… Thursday, October 12, 2017 Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in active surveillance programs, driving the need for more-accurate decision-making tools

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.

… Wednesday, February 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center. Published in the February